A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma

Starting soon

Conditions studied: Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable

In brief

This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary objective is to assess the outcomes of intention-to-treat (ITT) patients who received multidisciplinary conversion therapy. This therapy combines locoregional treatments (LRT, such as TACE or radiotherapy) with systemic therapy (anti-VEGF/tyrosine kinase inhibitors and immune checkpoint inhibitors) with the goal of down-staging tumors to allow for subsequent curative resection. The study plans to enroll 300 subjects. The exposure group will include approximately 100 patients with initially unresectable HCC who received the combined conversion therapy between January 2018 and December 2024. A control group of about 200 patients with initially resectable HCC who underwent direct radical surgery during the same period will be used for comparison. Data will be collected retrospectively from hospital electronic medical records and the HCC clinical database, with follow-up until December 2025.

Key facts

Study ID

NCT07368023

Run by

Ningbo Medical Center Lihuili Hospital

People needed

300

Starts

2026-01-25

Expected to finish

2026-05-31

Last updated by the study team

2026-01-26

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 16 years or older.
• Clinical and/or pathological diagnosis of hepatocellular carcinoma (HCC). China Liver Cancer (CNLC) stage I, II, or IIIA.
• Assessed by a multidisciplinary team (MDT) as having initially unresectable HCC.

You may not qualify if…

• Presence of extrahepatic metastasis.
• Presence of Cheng's type IV portal vein tumor thrombus (PVTT).
• Presence of Cheng's type II or III inferior vena cava tumor thrombus (IVCTT).

Where it is running

• Ningbo Medical Centre Lihuili Hospital — Ningbo, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.